TrialAntimicrobial agents and chemotherapy2007

Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.

Ana Marin-Niebla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.